ImmunoCellular Receives SPA From FDA For Phase 3 Trial In Glioblastoma
August 13, 2015 at 12:02 PM EDT
Shares of ImmunoCellular are up 24% after the company received an SPA from the FDA for a phase 3 trial in Glioblastoma.
 |
||||||||||||
|
||||||||||||
| About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map | ||||||||||||
Photos copyright by Jay Graham Photographer
